It's official: New FDA Commissioner Hahn wins Senate confirmation

Stephen Hahn
The Senate has confirmed Stephen Hahn as the next FDA commissioner. (MD Anderson Cancer Center)

The FDA has been plenty busy without an official commissioner since former head Scott Gottlieb stepped down earlier this year, but now it has a new chief to take on the job. 

Stephen Hahn, formerly chief medical officer of the University of Texas MD Anderson Cancer Center, secured confirmation from the Senate Thursday in a 72-18 vote, according to reports. He takes over the agency's sprawling brief, which covers pharmaceuticals, food safety, medical devices and tobacco.

Much of the conversation during Hahn’s confirmation process centered on vaping, which the FDA governs under its tobacco division, but the nominee did face questions about biosimilars, drug pricing, shortages, opioids and more. He didn't offer much in the way of specifics but pledged to always follow science and data over politics. 

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

On pricing, Hahn said the American people "want action." An oncologist, Hahn said “rarely a day goes by” that drug pricing doesn’t affect one of his patients.  

It’s an “urgent” issue, and the “American people want us to act on this," he told lawmakers at a hearing. Hahn said he’s “very interested” in the ways the FDA can stimulate competition and lower costs. 

RELATED: FDA Commissioner nominee Hahn promises to put science above politics 

Hahn replaces Gottlieb, a popular FDA commissioner who stepped down earlier this year after nearly two years at the helm. As commissioner, Gottlieb prioritized the opioid crisis and implemented measures aimed at fighting high drug costs, among other initiatives; he since has joined the board of Pfizer.

But work at the agency didn’t stop between the two commissioners. Two acting commissioners kept things moving, and the agency has approved several new drugs in recent months.

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.